Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab in Chinese Patients With RMS and PPMS
NCT07483450Phase 4Active, not recruiting
- Sponsor
- Roche
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ocrelizumab in multiple sclerosis (MS), primary progressive multiple sclerosis (PPMS), sponsored by Roche. Started Jul 2025; status: active, not recruiting.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NCT07483450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07483450.